A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Oct 31, 2012
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Neonates with persistent pulmonary hypertension of the newborn
- • Age \<=96 hours and \>=34 weeks gestational age
- • Oxygenation Index \>15 and \<60
- • Concurrent treatment with inhaled nitric oxide and \>=50% oxygen
- Exclusion Criteria:
- • Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation
- • Expected duration of mechanical ventilation \<48 hours
- • Profound hypoxemia
- • Life-threatening or lethal congenital anomaly
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Cleveland, Ohio, United States
Sacramento, California, United States
Cleveland, Ohio, United States
Gent, , Belgium
Little Rock, Arkansas, United States
Oklahoma City, Oklahoma, United States
Nashville, Tennessee, United States
Kansas City, Missouri, United States
Leicester, , United Kingdom
Stockholm, , Sweden
Leipzig, , Germany
Durham, North Carolina, United States
Bristol, , United Kingdom
Edegem, , Belgium
Madrid, , Spain
Paris, , France
Indianapolis, Indiana, United States
Nijmegen, , Netherlands
Tulsa, Oklahoma, United States
Seattle, Washington, United States
Aarhus N, , Denmark
Indianapolis, Indiana, United States
Washington, District Of Columbia, United States
Indianapolis, Indiana, United States
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Seattle, Washington, United States
Quebec, , Canada
Copenhagen ø, , Denmark
Lille, , France
Lille, , France
Marseille, , France
Paris, , France
Pavia, , Italy
Rotterdam, , Netherlands
Bergen, Haukeland, Norway
Esplugues De Llobregat, Barcelona / Spain, Spain
Leicester, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials